Clinical Trials Directory

Trials / Completed

CompletedNCT00943267

Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)

Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
52 (estimated)
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
Sex
Male
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

Recombinant human Activated Protein C (rhAPC) has been shown to reduce the mortality of patients with severe sepsis. The biological effects of APC are pleiotropic, and can be roughly divided in anticoagulant and cytoprotective effects. Lung infection and inflammation are associated with reduced bronchoalveolar levels of endogenous APC. Recent evidence derived from animal studies indicates that local administration of rAPC into the lungs exerts local anti-inflammatory and anticoagulant effects. In this study we propose to study the potential of locally administered APC, within a lung subsegment, to inhibit lipopolysaccharide (LPS) induced lung inflammation and coagulation in humans.

Conditions

Interventions

TypeNameDescription
DRUGDrotrecogin alphaDrotrecogin alpha is given intrabronchially by bronchoscopy at t=0
DRUGSaline (NaCl 0.9%)Normal saline is given intrabronchially by bronchoscopy at t=0
DRUGEndotoxinEndotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
PROCEDUREBronchoscopyBronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
PROCEDUREBlood samplingBlood sampling is done by venapuncture at t=0 and t=6

Timeline

Start date
2008-10-01
Primary completion
2010-08-01
Completion
2011-03-01
First posted
2009-07-22
Last updated
2011-03-16

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00943267. Inclusion in this directory is not an endorsement.